Sign up Australia
Proactive Investors - Run By Investors For Investors

Amryt Pharma’s Lojuxta ‘bad’ cholesterol treatment to be made available on NHS

The drug developer expects its top line to benefit from the decision from 2019 and beyond
cholesterol
Homozygous Familial Hypercholesterolaemia is an inherited condition which causes abnormally high levels of ‘bad’ cholesterol

Amryt Pharma PLC’s (LON:AMYT) Lojuxta Homozygous Familial Hypercholesterolaemia (HoFH) treatment is to be made available to NHS patients in England.

HoFH is a rare life-threatening disorder that causes abnormally high levels of low density lipoprotein (LDL) cholesterol.

Clinical trials showed Lojuxta can reduce the production and uptake of this ‘bad’ cholesterol, helping sufferers to get their cholesterol levels down to acceptable levels.

Amryt expects the treatment to be available to HoFH patients treated by NHS England during the fourth quarter of 2018.

Earnings impact

“We are delighted that NHS England has recognised the significant unmet need in the current treatment of HoFH in England and the potential Lojuxta has to significantly improve the lives of HoFH patients,” said chief executive Joe Wiley.

“This decision today is in line with our strategy to make Lojuxta available to more patients across Amryt's territories and it is estimated that funding approval will have a positive impact on revenue from 2019 and beyond.”

View full AMYT profile View Profile

Amryt Pharma PLC Timeline

Related Articles

woman at a microscope
August 02 2018
Currently undergoing phase III clinical trials, AP101 is being developed to treat Epidermolysis Bullosa, a condition which occurs prominently in children and makes skin fragile to even the faintest touch
Cancer cells
June 27 2018
The Nottingham-based privately-owned company has made an impressive fist of developing the OMIS (Opto-magnetic Imaging Spectroscopy) cancer detection system
picture of cannabis plants
March 24 2018
Control of the supply chain offers operational advantages and financial benefits.

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use